CEACAM5 and neoplasm: CEA-mediated tumor accumulation has been reported before in several clinical trials with anti-CEA antibodies [12–18], mainly in colorectal, liver, bone, thyroid, and lymph node lesions; however, none of the trials confirmed tumor CEA expression with immunohistochemistry.